Susceptibility to liver fibrosis in mice expressing a connective tissue growth factor transgene in hepatocytes # †
Open Access
- 27 August 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 50 (3) , 939-947
- https://doi.org/10.1002/hep.23102
Abstract
Connective tissue growth factor (CCN2) is a matricellular protein that is up-regulated in many fibrotic disorders and coexpressed with transforming growth factor β. CCN2 promotes fibrogenesis and survival in activated hepatic stellate cells, and injured or fibrotic liver contains up-regulated levels of CCN2 that are produced by a variety of different cell types, including hepatocytes. To investigate CCN2 action in vivo, transgenic FVB mice were created in which the human CCN2 gene was placed under the control of the albumin enhancer promoter to elevate hepatocyte CCN2 levels. Production of human CCN2 (hCCN2) messenger RNA and elevated CCN2 protein levels was demonstrated in transgenic livers, whereas levels of endogenous mouse CCN2 were comparable between transgenic and wild-type mice. Liver histology and liver function tests were unaffected in transgenic animals. However, after chronic administration of CCl4, α-smooth muscle actin (α-SMA)–expressing cells and collagen deposition were increased as a function of the dosage of the hCCN2 transgene (hccn2 +/+ > hccn2 +/− > hccn2−/−). Moreover, CCl4-induced serum hyaluronic acid, hepatic tissue levels of α-SMA or acid-soluble collagen, and messenger RNA expression of α-SMA, collagen α1 (I), matrix metalloprotease-2, or tissue inhibitor of metalloprotease-1 were greater in transgenic mice than in wild-type mice. Transgenic mice also exhibited enhanced hepatic deposition of collagen 2 weeks after bile duct ligation. Conclusion: Production of elevated CCN2 levels in hepatocytes of transgenic mice in vivo does not cause hepatic injury or fibrosis per se but renders the livers more susceptible to the injurious actions of other fibrotic stimuli. These studies support a central role of CCN2 in hepatic fibrosis and demonstrate a role of the microenvironment in regulating the profibrotic action of CCN2. (Hepatology 2009.)Keywords
This publication has 37 references indexed in Scilit:
- Skeletal Overexpression of Connective Tissue Growth Factor Impairs Bone Formation and Causes OsteopeniaEndocrinology, 2008
- Functions and mechanisms of action of CCN matricellular proteinsThe International Journal of Biochemistry & Cell Biology, 2008
- Regulation of CCN2 mRNA expression and promoter activity in activated hepatic stellate cellsJournal of Cell Communication and Signaling, 2008
- Connective tissue growth factor with a novel fibronectin binding site promotes cell adhesion and migration during rat oval cell activationHepatology, 2008
- CT domain of CCN2/CTGF directly interacts with fibronectin and enhances cell adhesion of chondrocytes through integrin α5β1FEBS Letters, 2006
- HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-β1Experimental & Molecular Medicine, 2005
- Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-βNature Cell Biology, 2002
- Overexpression of Connective Tissue Growth Factor/Hypertrophic Chondrocyte-Specific Gene Product 24 Decreases Bone Density in Adult Mice and Induces DwarfismBiochemical and Biophysical Research Communications, 2001
- The Connective Tissue Growth Factor/Cysteine- Rich 61/Nephroblastoma Overexpressed (CCN) FamilyEndocrine Reviews, 1999
- Establishment of the Enzyme-Linked Immunosorbent Assay for Connective Tissue Growth Factor (CTGF) and Its Detection in the Sera of Biliary AtresiaBiochemical and Biophysical Research Communications, 1998